ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AGL Angle Plc

14.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.00 13.50 14.50 14.00 14.00 14.00 186,248 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Business Services, Nec 1.04M -21.69M -0.0832 -1.68 36.48M
Angle Plc is listed in the Business Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 14p. Over the last year, Angle shares have traded in a share price range of 9.125p to 37.50p.

Angle currently has 260,580,547 shares in issue. The market capitalisation of Angle is £36.48 million. Angle has a price to earnings ratio (PE ratio) of -1.68.

Angle Share Discussion Threads

Showing 19576 to 19595 of 32750 messages
Chat Pages: Latest  794  793  792  791  790  789  788  787  786  785  784  783  Older
DateSubjectAuthorDiscuss
12/10/2022
13:59
Ah. See 2x200k now. Maybe a rollover...
bagpuss67
12/10/2022
13:59
Good post on the other threadOne point that hasn't been made yet is as follows. The Jefferies note of last week (6 October) has INCREASED its revenue predictions for Angle in this year and in all subsequent ones, relative to its initiation report of 19 January. The numbers are as follows:2022 now £2.0m revenue expected up from £1.9m2023 now £4.8m revenue expected up from £4.5m2024 now £14.3m revenue expected up from £13.7m2025 now £42.6m revenue expected up from £40.9m2026 also appears in the new note with £81.1m forecastClearly Jefferies are confident that Angle is not only meeting its expectations at the start of the year, but is exceeding them.
zeus19
12/10/2022
13:58
It’s a rollover.
purchaseatthetop
12/10/2022
13:56
400k at 57p. Unless its a rollover.
candlestick1
12/10/2022
13:38
200k at 57p. Painful.... I'm sure the brokers have an idea who it is and roughly how many they have...
bagpuss67
12/10/2022
13:33
Then of course when the seller clears they will try and close and probably go long to pump the price up...as they know there will be people who have bailed scrambling to get back in....
bagpuss67
12/10/2022
13:30
So someone finds out there is a seller in the market and then seeks to profit from that with some short spreadbets or CFDs. Then we have to suffer a whole load of people appearing on the thread with various theories and negative comments intended to scare small investors into bailing and perpetuating the fall.
bagpuss67
12/10/2022
13:05
Increased revenues are increased revenues. I'm sure if the revenue predictions were going down, not up, the doomsayers on here would be pointing it out. Plus as I stated, the £81.1m forecast for 2026 is new.
sicilian_kan
12/10/2022
13:00
I think its time the nurse took you out into the sunshine. :))
fevertreeman
12/10/2022
12:57
sk - Re your post 14661: in all fairness, surely that just reflects an adjustment for the strengthening USD and not much (if anything) else?
pldazzle
12/10/2022
12:48
Good post on the other threadOne point that hasn't been made yet is as follows. The Jefferies note of last week (6 October) has INCREASED its revenue predictions for Angle in this year and in all subsequent ones, relative to its initiation report of 19 January. The numbers are as follows:2022 now £2.0m revenue expected up from £1.9m2023 now £4.8m revenue expected up from £4.5m2024 now £14.3m revenue expected up from £13.7m2025 now £42.6m revenue expected up from £40.9m2026 also appears in the new note with £81.1m forecastClearly Jefferies are confident that Angle is not only meeting its expectations at the start of the year, but is exceeding them.
zeus19
12/10/2022
12:40
£2m this year also means £1.6m in H2, which they should have a good handle on at this stage.
sicilian_kan
12/10/2022
12:35
One point that hasn't been made yet is as follows. The Jefferies note of last week (6 October) has INCREASED its revenue predictions for Angle in this year and in all subsequent ones, relative to its initiation report of 19 January. The numbers are as follows:

2022 now £2.0m revenue expected up from £1.9m
2023 now £4.8m revenue expected up from £4.5m
2024 now £14.3m revenue expected up from £13.7m
2025 now £42.6m revenue expected up from £40.9m
2026 also appears in the new note with £81.1m forecast

Clearly Jefferies are confident that Angle is not only meeting its expectations at the start of the year, but is exceeding them.

sicilian_kan
12/10/2022
12:29
i am being sarcastic. My 2 pence...the CEO should get sacked. We need people like Sir Alan Sugar to run the company. The one who has a wealth of knowledge in business and marketing. Or the current CEO can move to Head of Research because he loves research and trials.

The company need re-organisation!

deanmatlazin
12/10/2022
12:29
The timing of the FDA clearance was a problem. A lot of the world actually takes holidays in the summer so any negotiations would have been slowed down. I am now expecting an RNS every two weeks or so. The Czech one would have been the easiest to negotiate simply because it is a small territory. Judge AN in another year.
purchaseatthetop
12/10/2022
12:29
This has been a Red flag all for months.Look at the fundamentals below provided by ANGLE PLC ..... DYORCash Flow PS - 5.96%Return On Equity (ROE) - 37.66 %Operating Margin - 1,714.02 %Net Debt - 24.85M
1liam
12/10/2022
12:23
So in summary, FTMs advice to AN is do less
asdb9
12/10/2022
12:21
deanmatinlazin, AN said that 3 of those companies were household names. So you are clearly wrong yet again.
sicilian_kan
12/10/2022
12:16
FTM. So what 'prongs' would you have sidelined?The prostrate study deal with Solaris with the potential to assist with its 750k patients testingOrThe establishment of 2 laboratories set up to offer trial assays and ad-hoc analysis of any cancer type sample, for a minimum £1k per sampleOrThe ovarian trial with the university of Vienna as part of FDA submissionOr seeking out 20+ pharma companies for deals pendingOr Discussions with UK. Clinics NHS/private to be revealedWhich of the above should have been cancelledAnd just to prove how pathetic your argument is you suggest that setting up a Czech distributor has exhausted resources. You have no idea. How long that took.You accuse the board of not pulling their weight, How do you know that, are you present at the meetings .You do not have a clue what you're talking about
asdb9
12/10/2022
12:15
Discussion with 20 companies. They are form Checz, Somalia, North Korea, Nepal, Afghanistan, Madagascar. LOL
deanmatlazin
Chat Pages: Latest  794  793  792  791  790  789  788  787  786  785  784  783  Older

Your Recent History

Delayed Upgrade Clock